CYDY - CytoDyn's Trial Starts And Other News: The Good Bad And Ugly Of Biopharma
CytoDyn Treats First Patient In Leronlimab Trial
CytoDyn Inc. (CYDY) reported that it has treated the first patient in its Phase 2 basket trial for 22 solid cancer tumors. The trial deals with a wide range of cancers and tumors such as throat, stomach, lungs, bladder, and uterine among others. The trial will also include 30 patients suffering from CCR5+ locally advanced or metastatic solid tumors. The drug candidate will be administered once in a week subcutaneously in 350 mg dosage. The participants will continue to receive standard of care chemotherapy.
CytoDyn reported